Evidence map›Paper›PMID 38561739›Full record

ArticleJournal of nanobiotechnology2024

High-performance pyrite nano-catalyst driven photothermal/chemodynamic synergistic therapy for Osteosarcoma.

Meirong Li, Minghua Wang, Junfeng Huang, Shiqi Tang, Jingyu Yang, Zhourui Xu, Gaixia Xu, Xin Chen, Jia Liu, Chengbin Yang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Meirong Li *Central Laboratory, The Second Affiliated Hospital of the Chinese University of Hong Kong, Shenzhen & Longgang District People's Hospital of Shenzhen, Shenzhen, Guangdong, 518172, P. R. China.
Minghua Wang *Pathology Department, The Second Affiliated Hospital of the Chinese University of Hong Kong, Shenzhen & Longgang District People's Hospital of Shenzhen, Shenzhen, Guangdong, 518172, P. R. China.
Junfeng Huang *School of Mechanical Engineering, Dongguan University of Technology, Dongguan, Guangdong, 523808, P. R. China.
Shiqi TangGuangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Shenzhen, Guangdong, 518060, P. R. China.
Jingyu YangGuangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Shenzhen, Guangdong, 518060, P. R. China.
Zhourui XuGuangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Shenzhen, Guangdong, 518060, P. R. China.
Gaixia XuGuangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Shenzhen, Guangdong, 518060, P. R. China.
Xin ChenGuangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Shenzhen, Guangdong, 518060, P. R. China.
Jia LiuCentral Laboratory, The Second Affiliated Hospital of the Chinese University of Hong Kong, Shenzhen & Longgang District People's Hospital of Shenzhen, Shenzhen, Guangdong, 518172, P. R. China. liujia870702@126.com.
Chengbin YangGuangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Shenzhen, Guangdong, 518060, P. R. China. cbyang@szu.edu.cn.
Shenzhen University · CNChinese University of Hong Kong, Shenzhen · CNDongguan University of Technology · CNShenzhen Second People's Hospital · CN

Funding

National Natural Science Foundation of China 81900264Natural Science Foundation of Guangdong Province 2021A1515012159
6 · The paper itself

Abstract

Osteosarcoma (OS) is an aggressive bone tumor with strong invasiveness, rapid metastasis, and dreadful mortality. Chemotherapy is a commonly used approach for OS treatment but is limited by the development of drug resistance and long-term adverse effects. To date, OS still lacks the curative treatment. Herein, we fabricated pyrite-based nanoparticles (FeS

Indexed as

Bone NeoplasmsNanoparticlesNeoplasmsOsteosarcomaSulfidesCell Line, TumorHumansHydrogen PeroxideIronPhotothermal TherapyHydrogen PeroxideIronpyriteSulfidesChemodynamic therapyFenton catalystOsteosarcomaPhotothermal therapyPyrite nanoparticle

Identifiers

PMID38561739
PMCPMC10983657
OpenAlexW4393381755

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.